Researcher.Life Logo

npj Vaccines : Impact Factor & More

eISSN: 2059-0105pISSN: 2059-0105
JournalOpen Access

Key Metrics

CiteScore
9.4
Eigenfactor
0.001 - 0.005
Impact Factor
5 - 10
Scite Index
0.91 5-Year SI
SJR
Q1Immunology
SNIP
1.99
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on npj Vaccines

npj Vaccines Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • DOAJ DOAJ
  • SJR SJR
Overview
Publisher NATURE PORTFOLIO
Language English
Frequency Continuous publication
Article Processing ChargesEUR 3190 | USD 3490 | GBP 2790
Publication Time11
Editorial Review ProcessAnonymous peer review
General Details
LanguageEnglish
Society/Institute/SponsorSealy Center for Vaccine Development at the University of Texas Medical Branch
FrequencyContinuous publication
Publication Start Year2015
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 11
Waiver PolicyVisit website
Editorial Review Detail
Editorial TeamVisit website
Review ProcessAnonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY
OA statementVisit website
View less

Planning to publish in npj Vaccines ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in npj Vaccines

Vaccination in individuals with Down syndrome: immune vulnerability, safety, efficacy and opportunities.
  • 19 May 2026
  • NPJ vaccines
Vaccine communication: a critical review of foundations, challenges, and future directions.
  • 18 May 2026
  • NPJ vaccines
Rural-urban differences in oral typhoid vaccine responses in Uganda: contribution of Schistosoma mansoni.
  • 16 May 2026
  • NPJ vaccines
Developing a durable, memory-driven, CspZ-targeting Lyme disease vaccine by rationale adjuvant selection.
  • 16 May 2026
  • NPJ vaccines
β-Glucan chitosan particle provides cross-protection against multi-drug-resistant Candida auris.
  • 16 May 2026
  • NPJ vaccines
Resurgence of invasive Haemophilus influenzae type b disease in France, 2017-2024: epidemiological, genomic, and immunological insights.
  • 13 May 2026
  • NPJ vaccines
Vaccination in individuals with Down syndrome: immune vulnerability, safety, efficacy and opportunities.
  • 19 May 2026
  • NPJ vaccines
Vaccine communication: a critical review of foundations, challenges, and future directions.
  • 18 May 2026
  • NPJ vaccines
Rural-urban differences in oral typhoid vaccine responses in Uganda: contribution of Schistosoma mansoni.
  • 16 May 2026
  • NPJ vaccines
Developing a durable, memory-driven, CspZ-targeting Lyme disease vaccine by rationale adjuvant selection.
  • 16 May 2026
  • NPJ vaccines
β-Glucan chitosan particle provides cross-protection against multi-drug-resistant Candida auris.
  • 16 May 2026
  • NPJ vaccines
Resurgence of invasive Haemophilus influenzae type b disease in France, 2017-2024: epidemiological, genomic, and immunological insights.
  • 13 May 2026
  • NPJ vaccines

FAQs on npj Vaccines